Disease outcome of inflammatory bowel disease patients: General outline of a Europe-wide population-based 10-year clinical follow-up study

Wolters, Frank; Rüssel, Maurice G.; Sijbrandij, Jildou; Schouten, Leo J.; Odes, Selwyn; Riis, Lene; Munkholm, Pia; Langholz, Ebbe; Buracco, Paolo; O’Moráin, Colm; Katsanos, K.H.; Tsianos, Epameinondas V.; Vermeire, Séverine; Zeijl, Gilbert Van; Limonard, Charles; Høie, Ole; Vatn, Morten H.; Moum, Bjørn; Stockbrügger, Reinhold W.

doi:10.1080/00365520600664250

Cited by 68 publications

(45 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients diagnosed younger than age 40 years experience more aggressive disease than those diagnosed later in life. 12,13 Patients who smoke, as well as those with disease localized to the small bowel, are at greater risk for poorer prognosis and early surgery, whereas disease exclusively in the colon is relatively protective. 13,58 Penetrating or stricturing disease, especially in children, is predictive of an aggressive disease course.…”

Section: Progress In Prognostic Evaluationmentioning

confidence: 98%

“…12,13 Patients who smoke, as well as those with disease localized to the small bowel, are at greater risk for poorer prognosis and early surgery, whereas disease exclusively in the colon is relatively protective. 13,58 Penetrating or stricturing disease, especially in children, is predictive of an aggressive disease course. 14 Although these characteristics are suggestive, their sensitivity and specificity are not high enough to determine therapeutic decisions.…”

Section: Progress In Prognostic Evaluationmentioning

confidence: 98%

See 1 more Smart Citation

Positioning biologic agents in the treatment of Crohnʼs disease

Hanauer

2009

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

One decade after the emergence of biologic therapy for Crohn's disease (CD), our treatment algorithms are beginning to change. Once reserved for patients with refractory disease, disease unresponsive to conventional therapies, or those requiring multiple courses of corticosteroids, there is increasing evidence that early, aggressive interventions with immunosuppressants or biologic therapies targeting tumor necrosis factor-alpha or alpha-4 integrins can alter the natural history of CD by reducing the transmural complications of structuring and fistulization and the nearly inevitable requisite for surgical resections. More recent trials are beginning to suggest that intervention with combination therapy for selected patients with a poor prognosis may modify the long-term course of CD. Selection of patients with features predicting a complex or progressive course and early, combined intervention is now possible. Future studies are still needed to best identify predictors of response to individual agents with differing mechanisms of action, as well as to optimize the risk-benefit of long-term maintenance therapy.

show abstract

Section: Progress In Prognostic Evaluationmentioning

confidence: 98%

Section: Progress In Prognostic Evaluationmentioning

confidence: 98%

Positioning biologic agents in the treatment of Crohnʼs disease

Hanauer

2009

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…Це обумовлено поширеністю хвороб у всьо-му світі, тенденцією до збільшення кількості випадків захворювань як серед дорослого населення, так і серед дітей, відсутністю чітких уявлень про етіологію та па-тогенез, тяжкістю і різноманітністю клінічних проявів, недостатньо розробленим і часто малоефективним ліку-ванням [1][2][3]. Це призводить до розвитку небезпечних для життя ускладнень, формування резистентних форм захворювань, втрати працездатності та інвалідизації осіб молодого віку, а іноді смерті пацієнтів [4][5][6]. За да-ними останніх епідеміологічних досліджень, щорічна захворюваність на НВК у Європі становить 10,4 ви-падку, а на ХК -5,6 випадку на 100 000 населення, при цьому найбільший градієнт спостерігається в країнах Скандинавії (24,5 та 9,2 на 100 000 відповідно).…”

Section: актуальністьunclassified

Застосування Препаратів 5-Аміносаліцилової Кислоти В лікуванні Запальних Захворювань Кишечника

Stepanov¹,

Stoykevich²,

Sorochan³

2021

GASTRO

View full text Add to dashboard Cite

show abstract

“…In Norway, Denmark and a European collaborative study, the rate of surgical resection after 10 years was 38, 55 and 40%, respectively [11,12,13]. At 30 years, it reached 64% in a population-based study from Olmsted County [14] and was above 80% in the National Cooperative Crohn’s Disease study from the USA [15].…”

Section: Cumulative Risk Of Complications and Surgerymentioning

confidence: 99%

Epidemiology of the Transition from Early to Late Crohn’s Disease

Louis

2012

Dig Dis

View full text Add to dashboard Cite

Phenotypically, the transition from early to late Crohn’s disease is characterized by the occurrence of complications including strictures, intra-abdominal fistulas and perianal fistulas, all of them leading to various types of surgeries and currently non-reversible tissue damage. It must, however, be kept in mind that this transition is not at all a uniform and linear process. According to these simple phenotypic criteria, Crohn’s disease can already be a late disease at diagnosis while in other patients, it can still be an early disease after 20 years of evolution. This simply highlights the relativity of time in this field, actually reflecting the nature, location and severity of the inflammatory process. The risk over time of the development of these complications has been described, first in cohort studies and then in population-based studies. Globally, at diagnosis, between 19 and 38% only of Crohn’s disease patients have complicated Crohn’s disease. After 10 years, between 56 and 65% of patients have developed either stricturing or penetrating complications. After 20 years, these numbers are between 61 and 88%. In parallel to these structural changes, changes in the immunobiology of the disease also seem to occur; the latter seem to happen quicker with major modification already within 2 years of the diagnosis. Beside these general figures, important questions remain pending. First, the real timing of these changes is still unclear. Second, the precise role of genetics and environment in the development of these changes remains to be clarified. Third, the correlation between changes in immunobiology and intestinal structural damages has not been specifically studied.

show abstract

Disease outcome of inflammatory bowel disease patients: General outline of a Europe-wide population-based 10-year clinical follow-up study

Abstract: This 10-year clinical follow-up study of a population-based European cohort of IBD patients provides updated information on disease outcome of these patient groups.

Cited by 68 publications

References 12 publications

Positioning biologic agents in the treatment of Crohnʼs disease

Positioning biologic agents in the treatment of Crohnʼs disease

Застосування Препаратів 5-Аміносаліцилової Кислоти В лікуванні Запальних Захворювань Кишечника

Epidemiology of the Transition from Early to Late Crohn’s Disease

Contact Info

Product

Resources

About